Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2012-02-09Clinical Trial Update: Clobazam in Subjects With Lennox-Gastaut Syndrome [Phase 2]
A Phase 2 trial evaluating clobazam in Lennox-Gastaut syndrome completed, with results posted in 2012.
-
FDA approval · 2012-02-01FDA Approved: PRIMIDONE — Supplemental Application (Lannett Company, Inc.)
FDA approves Lannett's supplemental ANDA for Primidone (PRIMIDONE), granting approval of a generic version.
-
FDA approval · 2012-01-31FDA Approved: LAMOTRIGINE KIT — Supplemental Application (OWP Pharmaceuticals, Inc.)
FDA approved a supplemental application for Lamotrigine Kit from OWP Pharmaceuticals, expanding the lamotrigine product offering. The approv…
-
CLINICAL_TRIALS trial_result · 2012-01-31Clinical Trial Update: Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy - Recruitment Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy - Recruitment Rhythm
The clinical trial evaluating stimulation of the anterior nucleus of the thalamus for epilepsy has completed recruitment.
-
FDA approval · 2012-01-27FDA Approved: EQUETRO — Supplemental Application (Validus Pharmaceuticals LLC)
The FDA approved a supplemental application for EQUETRO (carbamazepine) submitted by Validus Pharmaceuticals LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2012-01-26FDA Approved: ZONEGRAN — Supplemental Application (Advanz Pharma (US) Corp.)
The FDA approved a supplemental application for Zonegran (zonisamide) submitted by Advanz Pharma (US) Corp.
-
FDA approval · 2012-01-26FDA Approved: CARBAMAZEPINE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for the generic anticonvulsant carbamazepine from Chartwell RX, LLC.
-
FDA approval · 2012-01-24FDA Approved: CARBAMAZEPINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for carbamazepine submitted by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2012-01-24FDA Approved: CARBAMAZEPINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for carbamazepine from Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2012-01-20FDA Approved: OXCARBAZEPINE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' supplemental application for oxcarbazepine (generic anticonvulsant) under the ANDA process.
-
CLINICAL_TRIALS trial_result · 2012-01-16Clinical Trial Update: A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures [Phase 3]
Phase 3 long-term follow-up study of levetiracetam (L059) in epilepsy with partial-onset seizures completed; results posted in 2012.
-
CLINICAL_TRIALS trial_result · 2012-01-13Clinical Trial Update: Lamotrigine Extended-Release In Elderly Patients With Epilepsy [Phase 3]
A Phase 3 trial evaluating lamotrigine extended-release in elderly patients with epilepsy has completed, and results have been posted. The s…
-
FDA approval · 2011-12-29FDA Approved: LEVETIRACETAM — Supplemental Application (Torrent Pharmaceuticals Limited)
The FDA approved a supplemental application for levetiracetam from Torrent Pharmaceuticals Limited under the ANDA program.
-
FDA approval · 2011-12-28FDA Approved: OXCARBAZEPINE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved Glenmark's supplemental application for oxcarbazepine, allowing the marketing of a generic version of the antiepileptic drug.
-
CLINICAL_TRIALS research · 2011-12-20Clinical Trial Update: A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures [Phase 3]
Phase III open-label extension study evaluating gabapentin as adjunctive therapy in Japanese pediatric patients with partial seizures comple…
-
FDA approval · 2011-12-16FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for KEPPRA (levetiracetam) submitted by UCB, Inc., resulting in updated labeling for the drug. K…
-
EMA approval · 2011-12-16European Medicines Agency recommends authorisation of Vimpat syrup for patients who cannot swallow tablets
EMA recommends authorization of Vimpat syrup to treat epilepsy in patients who cannot swallow tablets, expanding the available formulation.
-
FDA approval · 2011-12-16FDA Approved: FELBAMATE — Original Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal's felbamate original application, a generic version of felbamate.
-
FDA approval · 2011-12-14FDA Approved: DILANTIN-125 — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for DILANTIN-125 (phenytoin) submitted by Viatris Specialty LLC.
-
CLINICAL_TRIALS research · 2011-12-08Clinical Trial Update: Lyrica (Pregabalin) Korean Post Marketing Surveillance Study
A completed post-marketing surveillance study of pregabalin (Lyrica) in Korea, with results posted in 2011, focusing on epilepsy and neuropa…
-
FDA label_change · 2011-11-29FDA Approved: LAMICTAL ODT — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for Lamictal ODT (lamotrigine) filed by GlaxoSmithKline, resulting in changes to the product labelin…
-
FDA approval · 2011-11-29FDA Approved: LAMICTAL XR — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for LAMICTAL XR (lamotrigine) from GlaxoSmithKline, indicating an updated approval related to the ex…
-
FDA label_change · 2011-11-29FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for Lamictal (lamotrigine) to update the product labeling.
-
FDA approval · 2011-11-25FDA Approved: GABAPENTIN — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for gabapentin submitted by BluePoint Laboratories.
-
CLINICAL_TRIALS trial_result · 2011-11-23Clinical Trial Update: Pediatric Epilepsy Study [Phase 3]
A Phase 3 pediatric epilepsy clinical trial sponsored by Novartis has completed, according to the ClinicalTrials.gov entry.